It antagonizes the glutamate induced neurotoxicity and also manifests analgesic effects
PMCID: PMC7037223
2013 Apr 15;447(1-2):75-93
While much of the available data comes from preclinical studies, interest in its biological activity continues to grow due to its interaction with multiple physiological pathways
Regulatory bodies (Food and Drug Administration, European Medicines Agency) classify BPC-157 as a research compound, not an approved treatment
Potential risks Serious risks and adverse events include: Allergic reaction to the medications or dye used in the injection Shoulder infection Depigmentation of the skin around the injection site (a whitening of the skin) Local fat atrophy around the injection site (thinning of the skin) Rupture of a tendon located in the path of the injection Nerve damage near the shoulder joint Bleeding at the injection site In addition to the above, corticosteroid injections increase the risk of: High blood pressure High blood sugar Decreased immune function Decrease in bone mineral density Bone infection (osteonecrosis) Reproductive hormone imbalance Metabolic changes (eg, increased appetite, weight gain, and fluid retention) These risks are typically associated with higher doses of corticosteroids, multiple injections, and for people with underlying medical conditions such as diabetes and heart problems
